Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific

This article was originally published in The Gray Sheet

Executive Summary

U.S. Department of Justice initiates inquiry relating to events leading up to the firm's Oct. 5 voluntary recall of its NIR ON Ranger with SOX coronary stent delivery system ("The Gray Sheet" Oct. 12, p. 28). The company "is not aware that [DoJ] is doing anything more than gathering information," Boston states, adding "we do not understand [DoJ's] interest in this matter." Separately, Boston is the subject of a recent class action lawsuit in the U.S. District Court for Massachusetts filed by the law firm of Berger & Montague relating to improperly recorded revenues for Japan ("The Gray Sheet" Nov. 9, p. 5)

You may also be interested in...



Abbott Prism Assays, Spectrum Of Product Launches Stalled By QSR Finding

Approval of Abbott Laboratories' Prism hepatitis B core antibody and HIV-1/2 assays likely will be delayed by FDA's finding that Abbott's Lake County, Illinois diagnostic manufacturing facility still does not comply with quality system regulations, the firm said

Investors And Deal-Makers See Medtech Continuing To Ride The Growth Wave Into 2020

The consensus among investors is that medtech has been the best-performing part of health care for the past three to four years, and investment levels remain good. Seemingly all-encompassing of late has been companies’ preoccupation with digital strategies, but there is a lot more to this unique industry than just digital.

UsernamePublicRestriction

Register

MT011084

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel